Dupilumab-Associated Adverse Events During Treatment of Allergic Diseases

Gandhi NA, Bennett BL, Graham NM, Pirozzi G, Stahl N, Yancopoulos GD (2016) Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov 15(1):35–50. https://doi.org/10.1038/nrd4624

Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, van As A, Gupta N (2001) Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 108(2):184–190. https://doi.org/10.1067/mai.2001.117880

Simpson EL, Bieber T, Guttman-Yassky E et al (2016) Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 375(24):2335–2348. https://doi.org/10.1056/NEJMoa1610020

Castro M, Corren J, Pavord ID (2018) Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med 378(26):2486–2496. https://doi.org/10.1056/NEJMoa1804092

Halling AS, Loft N, Silverberg JI, Guttman-Yassky E, Thyssen JP (2020) Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis. J Am Acad Dermatol 84:139–147. https://doi.org/10.2340/00015555-3882

Siegels D, Heratizadeh A, Abraham S et al (2021) Systemic treatments in the management of atopic dermatitis: a systematic review and meta-analysis. Allergy 76:1053–76. https://doi.org/10.1111/all.14631

Agache I, Song Y, Alonso-Coello P et al (2021) Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: a systematic review for the EAACI guidelines. Allergy 76(8):2337–2353. https://doi.org/10.1111/all.14809

Agache I, Song Y, Posso M et al (2021) Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: a systematic review for the EAACI biologicals guidelines. Allergy 76(1):45–58. https://doi.org/10.1111/all.14510

Tauber M, Apoil PA, Richet C et al (2019) Effect of dupilumab on atopic manifestations in patients treated for atopic dermatitis in real-life practice. Br J Dermatol 180(6):1551–1552. https://doi.org/10.1111/bjd.17629

Beck LA, Thaçi D, Hamilton JD et al (2014) Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 371(2):130–139. https://doi.org/10.1056/NEJMoa1314768

Hamilton JD, Suárez-Fariñas M, Dhingra N et al (2014) Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol 134(6):1293–1300. https://doi.org/10.1016/j.jaci.2014.10.013

Guttman-Yassky E, Bissonnette R, Ungar B et al (2019) Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol 143(1):155–172. https://doi.org/10.1016/j.jaci.2018.08.022

He H, Olesen CM, Pavel AB, Clausen ML, Wu J, Estrada Y, Zhang N, Agner T, Guttman-Yassky E (2020) Tape-strip proteomic profiling of atopic dermatitis on dupilumab identifies minimally invasive biomarkers. Front Immunol 11:1768. https://doi.org/10.3389/fimmu.2020.01768

Bangert C, Rindler K, Krausgruber T et al (2021) Persistence of mature dendritic cells, TH2A, and Tc2 cells characterize clinically resolved atopic dermatitis under IL-4Rα blockade. Science Immunol 6(55):eabe2749. https://doi.org/10.1126/sciimmunol.abe2749

Möbus L, Rodriguez E, Harder I et al (2021) Atopic dermatitis displays stable and dynamic skin transcriptome signatures. J Allergy Clin Immunol 147(1):213–223. https://doi.org/10.1016/j.jaci.2020.06.012

Chen X, Liu M, Wu S, Huang Z, Li X, Lai X, Bao H, Huang J, Chang L, Zhang G (2021) Treatment-emergent adverse events in dupilumab-treated patients with allergic diseases: a meta-analysis. Allergy 76(2):593–596. https://doi.org/10.1111/all.14610

Barnes AC, Blandford AD, Perry JD (2017) Cicatricial ectropion in a patient treated with dupilumab. Am J Ophthalmol Case Rep 7:120–122. https://doi.org/10.1016/j.ajoc.2017.06.017

Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC et al (2017) Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 389:2287–2303. https://doi.org/10.1016/S0140-6736(17)31191-1

de Bruin-Weller M, Thaçi D, Smith CH, Reich K et al (2018) Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). Br J Dermatol 178:1083–1101. https://doi.org/10.1111/bjd.16156

Wollenberg A, Ariens L, Thurau S, van Luijk C, Seegräber M, de Bruin-Weller M (2018) Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab-clinical characteristics and treatment. J Allergy Clin Immunol Pract 6:1778–1780. https://doi.org/10.1016/j.jaip.2018.01.034

Fukuda K, Ishida W, Kishimoto T, Fukushima A (2019) Development of conjunctivitis with a conjunctival proliferative lesion in a patient treated with dupilumab for atopic dermatitis. Allergol Int 68(3):383–384. https://doi.org/10.1016/j.alit.2018.12.012

Bakker DS, Ariens LFM, van Luijk C, van der Schaft J et al (2019) Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis. Br J Dermatol 180(5):1248–1249. https://doi.org/10.1111/bjd.17538

Faiz S, Giovannelli J, Podevin C, Jachiet M et al (2019) Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort. J Am Acad Dermatol 81:143–151. https://doi.org/10.1016/j.jaad.2019.02.053

Fargnoli MC, Esposito M, Ferrucci S, Girolomoni G et al (2019) Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis. J Dermatolog Treat 28:1–7. https://doi.org/10.1080/09546634.2019.1682503

Maudinet A, Law-Koune S, Duretz C, Lasek A, Modiano P, Tran THC (2019) Ocular surface diseases induced by dupilumab in severe atopic dermatitis. Ophthalmol Ther 8:485–490. https://doi.org/10.1007/s40123-019-0191-9

Shen E, Xie K, Jwo K, Smith J, Mosaed S (2019) Dupilumab-induced follicular conjunctivitis. Ocul Immunol Inflamm 27:1339–1341. https://doi.org/10.1080/09273948.2018.1533567

Tauber M, Apoil PA, Richet C, Laurent J et al (2019) Effect of dupilumab on atopic manifestations in patients treated for atopic dermatitis in real-life practice. Br J Dermatol 180:1551–1552. https://doi.org/10.1111/bjd.17629

Zirwas MJ, Wulff K, Beckman K (2019) Lifitegrast add-on treatment for dupilumab-induced ocular surface disease (DIOSD): a novel case report. JAAD Case Rep 5:34–36. https://doi.org/10.1016/j.jdcr.2018.10.016

Akinlade B, Guttman-Yassky E, de Bruin-Weller M et al (2019) Conjunctivitis in dupilumab clinical trials. Br J Dermatol 181(3):459–473. https://doi.org/10.1111/bjd.17869

Agnihotri G, Shi K, Lio PA (2019) A clinician's guide to the recognition and management of dupilumab-associated conjunctivitis. Drugs R D 19(4):311–318. https://doi.org/10.1007/s40268-019-00288-x

Simpson EL, Paller AS, Siegfried EC, Boguniewicz M et al (2020) Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical Trial. JAMA Dermatol 156:44–56. https://doi.org/10.1001/jamadermatol.2019.3336

Voorberg AN, den Dunnen WFA, Wijdh RHJ, de Bruin-Weller MS, Schuttelaar MLA (2020) Recurrence of conjunctival goblet cells after discontinuation of dupilumab in a patient with dupilumab-related conjunctivitis. J Eur Acad Dermatol Venereol 34(2):e64-e66. https://doi.org/10.1111/jdv.15914

Quint T, Brunner PM, Sinz C, Steiner I et al (2020) Dupilumab for the treatment of atopic dermatitis in an Austrian cohort-real-life data shows rosacea-like folliculitis. J Clin Med 9(4):1241. https://doi.org/10.3390/jcm9041241

Nettis E, Bonzano L, Patella V, Detoraki A, Trerotoli P, Lombardo C (2020) Italian DADReL (Dupilumab Atopic Dermatitis in Real Life) Study Group Dupilumab-associated conjunctivitis in patients with atopic dermatitis: a multicenter real-life experience. J Investig Allergol Clin Immunol 30(3):201–204. https://doi.org/10.18176/jiaci.0481

Nettis E, Guerriero S, Masciopinto L, Di Leo E, Macchia L (2020) Dupilumab-induced bilateral cicatricial ectropion in real life. J Allergy Clin Immunol Pract 8(2):728–729. https://doi.org/10.1016/j.jaip.2019.10.015

Cheng J, Jiang L, Morrow NC, Avdic A, Fairley JA, Ling JJ, Greiner MA (2021) Recognition of atopic keratoconjunctivitis during treatment with dupilumab for atopic dermatitis. J Am Acad Dermatol 85(1):265–267. https://doi.org/10.1016/j.jaad.2020.09.046

Jo CE, Georgakopoulos JR, Drucker AM, Piguet V, Yeung J (2020) Incidence of conjunctivitis and other ocular surface disorders in patients with long-term dupilumab use. J Cutan Med Surg 24(5):527–528. https://doi.org/10.1177/1203475420929920

Achten R, Bakker D, Ariens L, Lans A et al (2021) Long-term follow-up and treatment outcomes of conjunctivitis during dupilumab treatment in patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol Pract 9(3):1389–1392.e2. https://doi.org/10.1016/j.jaip.2020.09.042

Touhouche AT, Cassagne M, Berard E, Giordano-Labadie F, Didier A, Fournie P et al (2021) Incidence and risk factors for dupilumab associated ocular adverse events: a real-life prospective study. J Eur Acad Dermatol Venereol 35:172–179 (PubMed PMID: 32521566)

CAS  Article  Google Scholar 

Kimura A, Akeda A, Ikebukuro T, Hori J (2021) Serum IgE reduction and paradoxical eosinophilia associated with allergic conjunctivitis after dupilumab therapy. J Ophthalmic Inflamm Infec 11(1):3. https://doi.org/10.1186/s12348-020-00234-y

Bohner A, Topham C, Strunck J, Haynes D, Brazil M, Clements J, Simpson E, Chamberlain W (2021) Dupilumab-associated ocular surface disease: clinical characteristics, treatment, and follow-up. Cornea 40:584–589. https://doi.org/10.1097/ICO.0000000000002461

Paller AS, Siegfried EC, Thaçi D et al (2020) Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol 83(5):1282–1293. https://doi.org/10.1016/j.jaad.2020.06.054

Ayasse M, Lockshin B, Do BK, Kaiser R, Silverberg JI (2020) A case report of uveitis secondary to dupilumab treatment for atopic dermatitis. JAAD Case Rep 7:98–99. https://doi.org/10.1016/j.jdcr.2020.11.012

Uchida H, Kamata M, Nagata M, Fukaya S, Hayashi K, Fukuyasu A, Tanaka T, Ishikawa T, Ohnishi T, Tada Y (2020) Conjunctivitis in patients with atopic dermatitis treated with dupilumab is associated with higher baseline serum levels of immunoglobulin E and thymus and activation-regulated chemokine but not clinical severity in a real-world setting. J Am Acad Dermatol 82(5):1247–1249. https://doi.org/10.1016/j.jaad.2019.12.039

Barnett BP, Afshari NA (2020) Dupilumab-associated mucin deficiency (DAMD). Transl Vis Sci Technol 9(3):29. https://doi.org/10.1167/tvst.9.3.29

Wollenberg A, Blauvelt A, Guttman-Yassky E, Worm M et al (2021) Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol 184(3):437–449. https://doi.org/10.1111/bjd.19574.

Guttman-Yassky E, Blauvelt A, Eichenfield LF, Paller AS, Armstrong AW, Drew J, Gopalan R, Simpson EL (2020) Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b randomized clinical trial. JAMA Dermatol 156(4):411–420. https://doi.org/10.1001/jamadermatol.2020.0079

García-Posadas L, Hodges RR, Diebold Y, Dartt DA (2018) Context-dependent regulation of conjunctival goblet cell function by allergic mediators. Sci Rep 8(1):12162. https://doi.org/10.1038/s41598-018-30002-x

Austin CD, Gonzalez Edick M, Ferrando RE et al (2020) A randomized, placebo-controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER). Clin Exp Allergy 50(12):1342–1351. https://doi.org/10.1111/cea.13731

Wenzel S, Castro M, Corren J, Maspero J et al (2016) Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet 388:31–44. https://doi.org/10.1016/S0140-6736(16)30307-5

Rabe KF, Nair P, Brusselle G, Maspero JF et al (2018) Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med 378:2475–2485. https://doi.org/10.1056/NEJMoa1804093

Hirano I, Dellon ES, Hamilton JD, Collins MH et al (2020) Efficacy of dupilumab in a phase 2 randomized trial of adults with active eosinophilic esophagitis. Gastroenterology 158:111–122.e10. https://doi.org/10.1053/j.gastro.2019.09.042.

Agache I, Song Y, Rocha C, Beltran J et al (2020) Efficacy and safety of treatment with dupilumab for severe asthma: a systematic review of the EAACI guidelines-Recommendations on the use of biologicals in severe asthma. Allergy 75:1058–1068. https://doi.org/10.1111/all.14809

Thompson AM, Yu L, Hsiao JL, Shi VY (2021) Dermatology-ophthalmology collaborations are needed in dupilumab-associated ocular events. J Am Acad Dermatol 84(6):e279-e280. https://doi.org/10.1016/j.jaad.2021.01.043

Bansal A, Simpson EL, Paller AS et al (2021) Conjunctivitis in dupilumab clinical trials for adolescents with atopic dermatitis or asthma. Am J Clin Dermatol 22(1):101–115. https://doi.org/10.1007/s40257-020-00577-1

Waldman RA, DeWane ME, Sloan SB, King B, Grant-Kels JM (2021) Dupilumab ocular surface disease occurs predominantly in patients receiving dupilumab for atopic dermatitis: a multi-institution retrospective chart review. J Am Acad Dermatol 85(3):735–736. https://doi.org/10.1016/j.jaad.2019.07.031

Jo CE Finstad A, Georgakopoulos JR, Piguet V, Yeung J, Drucker AM (2021) Facial and neck erythema associated with dupilumab treatment: a systematic review. J Am Acad Dermatol 84(5):1339–1347. https://doi.org/10.1016/j.jaad.2021.01.012

de Beer FSA, Bakker DS, Haeck I et al (2019) Dupilumab facial redness: positive effect of itraconazole. JAAD Case Rep 5(10):888–891. https://doi.org/10.1016/j.jdcr.2019.07.020

de Wijs LEM, Nguyen NT, Kunkeler ACM, Nijsten T, Damman J, Hijnen DJ (2020) Clinical and histopathological characterization of paradoxical head and neck erythema in patients with atopic dermatitis treated with dupilumab: a case series. Br J Dermatol 183(4):745–749. https://doi.org/10.1111/bjd.18730

Albader SS, Alharbi AA, Alenezi RF, Alsaif FM (2019) Dupilumab side effect in a patient with atopic dermatitis: a case report study. Biologics 13:79–82. https://doi.org/10.2147/BTT.S195512

Herz S, Petri M, Sondermann W (2019) New alcohol flushing in a patient with atopic dermatitis under therapy with dupilumab. Dermatol Ther 32(1):e12762.: https://doi.org/10.1111/dth.12762

Soria A, Du-Thanh A, Seneschal J, Jachiet M, Staumont-Sallé D, Barbarot S (2019) GREAT Research Group. Development or exacerbation of head and neck dermatitis in patients treated for atopic dermatitis with dupilumab. JAMA Dermatol 155(11):1312–1315 https://doi.org/10.1001/jamadermatol.2019.2613

Yamane MLM, Belsito DV, Glass LRD (2019) Two differing presentations of periocular dermatitis as a side effect of dupilumab for atopic dermatitis. Orbit 38(5):390–394. https://doi.org/10.1080/01676830.2018.1553190

Zhu GA, Chen JK, Chiou A, Ko J, Honari G (2019) Assessment of the development of new regional dermatoses in patients treated for atopic dermatitis with dupilumab. JAMA Dermatol 155(7):850–852. https://doi.org/10.1001/jamadermatol.2019.0109

Igelman SJ, Na C, Simpson EL (2020) Alcohol-induced facial flushing in a patient with atopic dermatitis treated with dupilumab. JAAD Case Rep 6(2):139–140. https://doi.org/10.1016/j.jdcr.2019.12.002

Muzumdar S, Zubkov M, Waldman R, DeWane ME, Wu R, Grant-Kels JM (2020) Characterizing dupilumab facial redness in children and adolescents: a single-institution retrospective chart review. J Am Acad Dermatol 83(5):1520–1521. https://doi.org/10.1016/j.jaad.2020.06.1003

Napolitano M, Scalvenzi M, Fabbrocini G, Cinelli E, Patruno C (2019) Occurrence of psoriasiform eruption during dupilumab therapy for adult atopic dermatitis: a case series. Dermatol Ther 32(6):e13142. https://doi.org/10.1111/dth.13142

Gori N, Caldarola G, Pirro F, De Simone C, Peris K (2019) A case of guttate psoriasis during treatment with dupilumab. Dermatol Ther 32(5):e12998. https://doi.org/10.1111/dth.12998

Stout M, Guitart J, Tan T, Silverberg JI (2019) Psoriasis-like dermatitis developing in a patient with atopic dermatitis treated with dupilumab. Dermatitis 30(6):376–378. https://doi.org/10.1097/DER.0000000000000509

Gambichler T, Reuther J, Richards C, Doerler M (2020) Dupilumab-induced psoriatic erythroderma with characteristic cytokine and antimicrobial peptide expression pattern in a patient with long standing atopic dermatitis. Int J Dermatol 59(9):1160–1162. https://doi.org/10.1111/ijd.15003

Matsuda T, Yamada H, Hida N, Nakaizumi T, Yamada E, Satoh H, Hizawa N (2020) An asthmatic case of psoriasiform eruption caused by administration of dupilumab. Allergol Int 69(3):478–479. https://doi.org/10.1016/j.alit.2020.02.004

D'Ambra I, Babino G, Fulgione E, Calabrese G, Ronchi A, Alfano R, Argenziano G, Piccolo V (2020) Psoriasis onset under dupilumab treatment in two patients affected by atopic dermatitis and one patient affected by alopecia areata: clinical and dermoscopic patterns. Dermatol Ther 33(6):e14169. https://doi.org/10.1111/dth.14169

DeGrazia TM, Raji K, Alshamekh S, Chisolm S (2020) Psoriatic plaques after initiation of dupilumab therapy. Dermatitis 31(4):e36-e37. https://doi.org/10.1097/DER.0000000000000570

Mirza FN, Wang A, Ramachandran SM, Damsky W, Cohen JM (2021) Dupilumab induced phenotype switch from atopic dermatitis to psoriasis is characterized by de novo IL-17A expression: a case report. Br J Dermatol 185(2):432–434. https://doi.org/10.1111/bjd.20064

Jaulent L, Staumont-Sallé D, Tauber M, Paul C, Aubert H, Marchetti A, Sassolas B, Valois A, Nicolas JF, Nosbaum A (2021) for GREAT Research Group. De novo psoriasis in atopic dermatitis patients treated with dupilumab: a retrospective cohort. J Eur Acad Dermatol Venereol 35(4):e296-e297. https://doi.org/10.1111/jdv.17050

Tracey EH, Elston C, Feasel P, Piliang M, Michael M, Vij A (2018) Erythrodermic presentation of psoriasis in a patient treated with dupilumab. JAAD Case Rep 4(7):708–710. https://doi.org/10.1016/j.jdcr.2018.05.014

Napolitano M, Caiazzo G, Fabbrocini G, Balato A, Di Caprio R, Scala E, Scalvenzi M, Patruno C (2021) Increased expression of interleukin-23A in lesional skin of patients with atopic dermatitis with psoriasiform reaction during dupilumab treatment. Br J Dermatol 184(2):341–343. https://doi.org/10.1111/bjd.19459

Chiba T, Nagai T, Osada SI, Manabe M (2019) Diagnosis of mycosis fungoides following administration of dupilumab for misdiagnosed atopic dermatitis. Acta Derm Venereol 99(9):818–819. https://doi.org/10.2340/00015555-3208

Hollins LC, Wirth P, Fulchiero GJ Jr, Foulke GT (2020) Long-standing dermatitis treated with dupilumab with subsequent progression to cutaneous T-cell lymphoma. Cutis 106(2):E8–E11. https://doi.org/10.12788/cutis.0074

Espinosa ML, Nguyen MT, Aguirre AS, Martinez-Escala ME et al (2020) Progression of cutaneous T-cell lymphoma after dupilumab: case review of 7 patients. J Am Acad Dermatol 83(1):197–199. https://doi.org/10.1016/j.jaad.2020.03.050

Miyashiro D, Vivarelli AG, Gonçalves F, Cury-Martins J, Sanches JA (2020) Progression of mycosis fungoides after treatment with dupilumab: a case report. Dermatol Ther 33(6):e13880. https://doi.org/10.1111/dth.13880

Legendre L, Barnetche T, Mazereeuw-Hautier J, Meyer N, Murrell D, Paul C (2015) Risk of lymphoma in patients with atopic dermatitis and the role of topical treatment: a systematic review and meta-analysis. J Am Acad Dermatol 72(6):992–1002. https://doi.org/10.1016/j.jaad.2015.02.1116

Russomanno K, Carver DeKlotz CM (2020) Acceleration of cutaneous T-cell lymphoma following dupilumab administration. JAAD Case Rep 8:83–85. https://doi.org/10.1016/j.jdcr.2020.12.010

Steck O, Bertschi NL, Luther F, van den Berg J, Winkel DJ, Holbro A, Schlapbach C (2021) Rapid and sustained control of itch and reduction in Th2 bias by dupilumab in a patient with Sézary syndrome. J Eur Acad Dermatol Venereol 35(6):1331–1337. https://doi.org/10.1111/jdv.17001

Smogorzewski J, Sierro T, Compoginis G, Kim G (2019) Remission of alopecia universalis in a patient with atopic dermatitis treated with dupilumab. JAAD Case Rep 5(2):116–117. https://doi.org/10.1016/j.jdcr.2018.11.007

Beaziz J, Bouaziz JD, Jachiet M, Fite C, Lons-Danic D (2021) Dupilumab-induced psoriasis and alopecia areata: case report and review of the literature. Ann Dermatol Venereol 148(3):198–201. https://doi.org/10.1016/j.annder.2021.02.003

Barroso-García B, Rial MJ, Molina A, Sastre J (2018) Alopecia areata in severe atopic dermatitis treated with dupilumab. J Investig Allergol Clin Immunol 28(6):420–421. https://doi.org/10.18176/jiaci.0301

Mitchell K, Levitt J (2018) Alopecia areata after dupilumab for atopic dermatitis. JAAD Case Rep 4(2):143–144. https://doi.org/10.1016/j.jdcr.2017.11.020

Yazdanyar S, Jemec GBE (2019) Alopecia areata after treatment with dupilumab. Dermatitis 30(2):175–176. https://doi.org/10.1097/DER.0000000000000458

Salgüero-Fernández I, Gonzalez de Domingo MA, Suarez D, Roustan-Gullón G (2019) Dermatitis and alopecia in a patient treated with dupilumab: a new adverse effect? Clin Exp Dermatol 44(3):e41-e43. https://doi.org/10.1111/ced.13858

Flanagan K, Sperling L, Lin J (2019) Drug-induced alopecia after dupilumab therapy. JAAD Case Rep 5(1):54–56. https://doi.org/10.1016/j.jdcr.2018.10.010

Patruno C, Napolitano M, Ferrillo M, Fabbrocini G (2019) Dupilumab and alopecia: a Janus effect. Dermatol Ther 32(5):e13023. https://doi.org/10.1111/dth.13023

Barbarin C, Hosteing S, Nosbaum A, Allouchery M, Celerier P (2019) Early onset of alopecia areata after dupilumab introduction in a patient with atopic dermatitis. Eur J Dermatol 29(5):542–543. https://doi.org/10.1684/ejd.2019.3626

Penzi, LR, Yasuda M, Manatis-Lornell A, Hagigeorges D, Senna MM (2018) Hair regrowth in a patient with long-standing alopecia totalis and atopic dermatitis treated with dupilumab. JAMA Dermatol 154(11):1358–1360. https://doi.org/10.1001/jamadermatol.2018.2976

Darrigade A-S, Legrand A, Andreu N, Jacquemin C, Boniface K, Taïeb A, Seneschal J (2018) Dual efficacy of dupilumab in a patient with concomitant atopic dermatitis and alopecia areata. Br J Dermatol 179(2):534–536. https://doi.org/10.1111/bjd.16711

Ludriksone L, Elsner P, Schliemann S (2019) Simultaneous effectiveness of dupilumab in atopic dermatitis and alopecia areata in two patients. J Dtsch Dermatol Ges 17(12):1278–1280. https://doi.org/10.1111/ddg.13990

Alniemi DT, McGevna L (2019) Dupilumab treatment for atopic dermatitis leading to unexpected treatment for alopecia universalis. JAAD Case Rep 5(2):111–112. https://doi.org/10.1016/j.jdcr.2018.11.006

Uchida H, Kamata M, Watanabe A, Agematsu A et al (2019) Dupilumab improved alopecia areata in a patient with atopic dermatitis: a case report. Acta Derm Venereol 99(7):675–676. https://doi.org/10.2340/00015555-3183

Call JE, Sahni S, Zug KA (2020) Effectiveness of dupilumab in the treatment of both atopic dermatitis and alopecia universalis. Clin Case Rep 8(8):1337–1339. https://doi.org/10.1002/ccr3.2915

Babino G, Fulgione E, D'Ambra I, Calabrese G, Alfano R, Argenziano G (2020) Rapid hair regrowth induced by dupilumab in a patient affected by alopecia totalis of 28 years' duration: Clinical and dermoscopic features. Dermatol Ther 33(4):e13582. https://doi.org/10.1111/dth.13582

Harada K, Irisawa R, Ito T, Uchiyama M, Tsuboi R (2020) The effectiveness of dupilumab in patients with alopecia areata who have atopic dermatitis: a case series of seven patients. Br J Dermatol 183(2):396–397. https://doi.org/10.1111/bjd.18976

Gruenstein D, Malik K, Levitt J (2020) Full scalp hair regrowth in a 4-year-old girl with alopecia areata and atopic dermatitis treated with dupilumab. JAAD Case Rep 6(12):1286–1287. https://doi.org/10.1016/j.jdcr.2020.10.010

Muto J, Yoshida S, Doi C, Habu M, Sayama K (2021) Dupilumab treatment of atopic dermatitis leading to successful treatment of alopecia universalis: a Japanese case report. J Dermatol 48(2):e72-e73. https://doi.org/10.1111/1346-8138.15631

Kageyama R, Ito T, Hanai S, Morishita N, Nakazawa S, Fujiyama T, Honda T, Tokura Y (2021) Immunological properties of atopic dermatitis-associated alopecia areata. Int J Mol Sci 22(5):2618. https://doi.org/10.3390/ijms22052618

Menzella F, Montanari G, Patricelli G, Cavazza A, Galeone C, Ruggiero P, Bagnasco D, Facciolongo N (2019) A case of chronic eosinophilic pneumonia in a patient treated with dupilumab. Ther Clin Risk Manag 15:869–875. https://doi.org/10.2147/TCRM.S207402

Willsmore ZN, Woolf RT, Hughes C, Menon B, Kirkham B, Smith CH, Pink AE (2019) Development of inflammatory arthritis and enthesitis in patients on dupilumab: a case series. Br J Dermatol 181(5):1068–1070. https://doi.org/10.1111/bjd.18031

Bridgewood C, Sharif K, Freeston J, Saleem B (2021) Regulation of entheseal IL-23 expression by IL-4 and IL-13 as an explanation for arthropathy development under dupilumab therapy. Rheumatology (Oxford) 60(5):2461–2466. https://doi.org/10.1093/rheumatology/keaa568

De Wijs LEM, van der Waa JD, de Jong PHP, Hijnen DJ (2020) Acute arthritis and arthralgia as an adverse drug reaction to dupilumab. Clin Exp Dermatol 45(2):262–263. https://doi.org/10.1111/ced.14050

Bostan E, Gülseren D, Özsoy Z, Bilge Ergen F (2022) Reactivation of inflammatory monoarthritis during dupilumab treatment used for prurigo nodularis. Arch Rheumatol 37 in press

Brough HA, Nadeau KC, Sindher SB, Alkotob SS, Chan S, Bahnson HT, Leung DYM, Lack G (2020) Epicutaneous sensitization in the development of food allergy: What is the evidence and how can this be prevented? Allergy 75(9):2185–2205. https://doi.org/10.1111/all.14304

Woodward DF, Hawley SB, Williams LS, Ralston TR, Protzman CE, Spada CS, Nieves AL (1990) Studies on the ocular pharmacology of prostaglandin D2. Invest Ophthalmol Vis Sci 31(1):138–146 (PMID: 2298534)

CAS  PubMed  Google Scholar 

Thyssen JP (2018) Could conjunctivitis in patients with atopic dermatitis treated with dupilumab be caused by colonization with Demodex and increased interleukin-17 levels? Br J Dermatol 178(5):1220. https://doi.org/10.1111/bjd.16330

Kim JT, Lee SH, Chun YS, Kim JC (2011) Tear cytokines and chemokines in patients with Demodex blepharitis. Cytokine 53(1):94–99. https://doi.org/10.1016/j.cyto.2010.08.009

Guenova E, Skabytska Y, Hoetzenecker W, Weindl G et al (2015) IL 4 abrogates T(H)17 cell-mediated inflammation by selective silencing of IL-23 in antigen-presenting cells. Proc Natl Acad Sci USA 112:2163–2168. https://doi.org/10.1073/pnas.1416922112

Bakker DS, van der Wal MM, Heeb LEM et al (2021) Early and long-term effects of dupilumab treatment on circulating T-cell functions in moderate-to-severe atopic dermatitis patients. J Invest Dermatol 141(8):1943–1953. https://doi.org/10.1016/j.jid.2021.01.022

Caldarola G, Pirro F, Di Stefani A, Talamonti M et al (2020) Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature. Expert Opin Biol Ther 20(6):665–672. https://doi.org/10.1080/14712598.2020.1727439

Gilhar A, Laufer-Britva R, Keren A, Paus R (2019) Frontiers in alopecia areata pathobiology research. J Allergy Clin Immunol 144(6):1478–1489. https://doi.org/10.1016/j.jaci.2019.08.035

Atwa MA, Youssef N, Bayoumy NM (2016) T-helper 17 cytokines (interleukins 17, 21, 22, and 6, and tumor necrosis factor-α) in patients with alopecia areata: association with clinical type and severity. Int J Dermatol 55(6):666–672. https://doi.org/10.1111/ijd.12808

Inui S, Noguchi F, Nakajima T, Itami S (2013) Serum thymus and activation-regulated chemokine as disease activity and response biomarker in alopecia areata. J Dermatol 40(11):881–885. https://doi.org/10.1111/1346-8138.12273

Trichot C, Faucheux L, Karpf L, Grandclaudon M, Pattarini L, Bagot M, Mahévas T, Jachiet M, Saussine A, Bouaziz JD, Soumelis V (2021) TH cell diversity and response to dupilumab in patients with atopic dermatitis. J Allergy Clin Immunol 147(2):756–759. https://doi.org/10.1016/j.jaci.2020.05.037

Bieber T (2022) Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. Nat Rev Drug Discov 21(1):21–40. https://doi.org/10.1038/s41573-021-00266-6

Guttman-Yassky E, Blauvelt A, Eichenfield LF, Paller AS, Armstrong AW, Drew J, Gopalan R, Simpson EL (2020) Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b randomized clinical trial. JAMA Dermatol 156(4):411–420. https://doi.org/10.1001/jamadermatol.2020.0079

留言 (0)

沒有登入
gif